REGENXBIO Inc.

Healthcare

NASDAQ:RGNX · NASDAQ Global Select

Market Cap $403.24M Beta 1.03 P/E (TTM) -1.5

$7.80 +1.97%

+$0.16 today

52W Low $5.46High $16.19

Vol 2.54M · Avg 1.24M

EPS (TTM) -$5.53Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-0.76%

Period High

$15.98

Period Low

$5.65

Latest

$7.80

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B

MoonLake Immunotherapeutics

NASDAQ:MLTX

$1.42B

Absci Corporation

NASDAQ:ABSI

$1.13B

Ventyx Biosciences, Inc.

VTYX

$1.00B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$991.43M

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

$804.47M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

$499.50M

Prothena Corporation plc

NASDAQ:PRTA

$461.76M

Verastem, Inc.

NASDAQ:VSTM

$286.46M

Gossamer Bio, Inc.

GOSS

$39.26M

What is the latest RGNX filing?

The latest filing shown is SC 13G/A dated Jun 4, 2026.

How many recent filings does RGNX have?

Intrinsic Alpha currently shows 20 recent filings for RGNX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.